THAR: קונצנזוס שווי הוגן Tharimmune Inc
The business model of Tharimmune, Inc. (THAR) relies on the efficiency of developing antibodies against hepatic pruritus, where successful test completion serves as the key factor. The US company creates innovative therapies for oncology and orphan diseases, attracting investments based on trial progress. The current metric is 5.02. The asset's dynamics are reflected in the quotes provided below on the GURU.Markets platform.
%20-%20%D7%AA%D7%97%D7%96%D7%99%D7%AA%20%D7%A7%D7%95%D7%A0%D7%A6%D7%A0%D7%96%D7%95%D7%A1%20%D7%90%D7%A0%D7%9C%D7%99%D7%A1%D7%98%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mvj9owew.wip-79mfnr4&start=20220704&end=20261022&filename=GURU_Markets_-_THAR_-_Tharimmune-Inc._-_Analyst-Consensus-Forecast "THAR - תחזית קונצנזוס אנליסטים Tharimmune, Inc. בטווח 21.02.2024 - 18.02.2026 | 👁️GURU.Markets👁️")
פילוחים אנליטיים של חברת Tharimmune Corp (THAR)
For Tharimmune, Inc. (THAR), the analysts' calculated price target serves as a leading indicator of market confidence in the success of its antibody platform for the therapy of hepatic pruritus. The dynamics of this metric aggregate expert expectations regarding clinical trial results, where a sharp decline in value signals commercialization risks, while a deep discount opens opportunities to enter a high-quality asset.